Literature DB >> 19767446

Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation.

Rachel L Thomas1, Christopher J Langmead, Martyn D Wood, R A John Challiss.   

Abstract

A new class of subtype-selective muscarinic acetylcholine (mACh) receptor agonist that activates the receptor through interaction at a site distinct from the orthosteric acetylcholine binding site has been reported recently. Here, we have compared the effects of orthosteric (oxotremorine-M, arecoline, pilocarpine) and allosteric [4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl] piperidine (AC-42); 1-[3-(4-butyl-1-piperidinyl)propyl]-3,4-dihydro-2(1H)-quinolinone (77-LH-28-1)] agonists on M(1) mACh receptor internalization and down-regulation, as well as functional coupling in a Chinese hamster ovary (CHO) cell line. In contrast to full and partial orthosteric agonists, which cause significant receptor internalization and down-regulation, prolonged exposure to AC-42 did not significantly alter either cell-surface or total cellular M(1) mACh receptor expression. 77-LH-28-1, an AC-42 homolog, did cause some receptor internalization, but not down-regulation. The presence of atropine completely prevented the orthosteric agonist-induced adaptive changes in receptor populations; however, in contrast, the copresence of atropine and AC-42 significantly increased both cell-surface receptor and total M(1) mACh receptor expression. Maximal phosphoinositide hydrolysis responses to the partial agonist arecoline were similar in CHO-M(1) cells pretreated for 24 h with either AC-42 or vehicle; in contrast, these responses were markedly reduced when cells were pretreated with oxotremorine-M or pilocarpine. These data indicate that, whereas AC-42 binding to the M(1) mACh receptor can initiate signal transduction, the AC-42-liganded receptor is resistant to the usual mechanisms regulating receptor internalization and down-regulation. In addition, our data suggest unusual interactions between allosteric agonists and orthosteric antagonists to regulate cell-surface and total cellular receptor expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19767446      PMCID: PMC2784718          DOI: 10.1124/jpet.109.160242

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

1.  Discovery of an ectopic activation site on the M(1) muscarinic receptor.

Authors:  Tracy A Spalding; Carol Trotter; Niels Skjaerbaek; Terri L Messier; Erika A Currier; Ethan S Burstein; Donghui Li; Uli Hacksell; Mark R Brann
Journal:  Mol Pharmacol       Date:  2002-06       Impact factor: 4.436

2.  Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators.

Authors:  Lauren T May; Yvonne Lin; Patrick M Sexton; Arthur Christopoulos
Journal:  J Pharmacol Exp Ther       Date:  2004-08-27       Impact factor: 4.030

3.  An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission.

Authors:  Jana K Shirey; Zixiu Xiang; Darren Orton; Ashley E Brady; Kari A Johnson; Richard Williams; Jennifer E Ayala; Alice L Rodriguez; Jürgen Wess; David Weaver; Colleen M Niswender; P Jeffrey Conn
Journal:  Nat Chem Biol       Date:  2007-12-02       Impact factor: 15.040

Review 4.  Molecular biology of muscarinic acetylcholine receptors.

Authors:  J Wess
Journal:  Crit Rev Neurobiol       Date:  1996

Review 5.  International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors.

Authors:  M P Caulfield; N J Birdsall
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

6.  Hm1 muscarinic cholinergic receptor internalization requires a domain in the third cytoplasmic loop.

Authors:  J Lameh; M Philip; Y K Sharma; O Moro; J Ramachandran; W Sadée
Journal:  J Biol Chem       Date:  1992-07-05       Impact factor: 5.157

7.  Roles of phosphorylation-dependent and -independent mechanisms in the regulation of M1 muscarinic acetylcholine receptors by G protein-coupled receptor kinase 2 in hippocampal neurons.

Authors:  Jonathon M Willets; Stefan R Nahorski; R A John Challiss
Journal:  J Biol Chem       Date:  2005-03-02       Impact factor: 5.157

8.  Differential role of beta-arrestin ubiquitination in agonist-promoted down-regulation of M1 vs M2 muscarinic acetylcholine receptors.

Authors:  Valerie A Mosser; Kymry T Jones; Katie M Hoffman; Nael A McCarty; Darrell A Jackson
Journal:  J Mol Signal       Date:  2008-12-03

9.  Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation.

Authors:  Lei Ma; Matthew A Seager; Matthew Seager; Marion Wittmann; Marlene Jacobson; Denise Bickel; Maryann Burno; Keith Jones; Valerie Kuzmick Graufelds; Guangping Xu; Michelle Pearson; Alexander McCampbell; Renee Gaspar; Paul Shughrue; Andrew Danziger; Christopher Regan; Rose Flick; Danette Pascarella; Susan Garson; Scott Doran; Constantine Kreatsoulas; Lone Veng; Craig W Lindsley; William Shipe; Scott Kuduk; Cyrille Sur; Gene Kinney; Guy R Seabrook; William J Ray
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

Review 10.  Muscarinic acetylcholine receptors as CNS drug targets.

Authors:  Christopher J Langmead; Jeannette Watson; Charlie Reavill
Journal:  Pharmacol Ther       Date:  2007-12-20       Impact factor: 12.310

View more
  17 in total

1.  Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models.

Authors:  Gregory J Digby; Meredith J Noetzel; Michael Bubser; Thomas J Utley; Adam G Walker; Nellie E Byun; Evan P Lebois; Zixiu Xiang; Douglas J Sheffler; Hyekyung P Cho; Albert A Davis; Natali E Nemirovsky; Sarah E Mennenga; Bryan W Camp; Heather A Bimonte-Nelson; Jacob Bode; Kimberly Italiano; Ryan Morrison; J Scott Daniels; Colleen M Niswender; M Foster Olive; Craig W Lindsley; Carrie K Jones; P Jeffrey Conn
Journal:  J Neurosci       Date:  2012-06-20       Impact factor: 6.167

Review 2.  Regulation of G protein-coupled receptors by allosteric ligands.

Authors:  J Robert Lane; Alaa Abdul-Ridha; Meritxell Canals
Journal:  ACS Chem Neurosci       Date:  2013-02-21       Impact factor: 4.418

Review 3.  Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

Authors:  Briana J Davie; Arthur Christopoulos; Peter J Scammells
Journal:  ACS Chem Neurosci       Date:  2013-05-23       Impact factor: 4.418

Review 4.  Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.

Authors:  Bruce J Melancon; James C Tarr; Joseph D Panarese; Michael R Wood; Craig W Lindsley
Journal:  Drug Discov Today       Date:  2013-09-17       Impact factor: 7.851

5.  Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs.

Authors:  Jerri M Rook; Masahito Abe; Hyekyung P Cho; Kellie D Nance; Vincent B Luscombe; Jeffrey J Adams; Jonathan W Dickerson; Daniel H Remke; Pedro M Garcia-Barrantes; Darren W Engers; Julie L Engers; Sichen Chang; Jarrett J Foster; Anna L Blobaum; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2017-01-10       Impact factor: 4.418

6.  Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.

Authors:  Kwang H Ahn; Mariam M Mahmoud; Debra A Kendall
Journal:  J Biol Chem       Date:  2012-02-16       Impact factor: 5.157

Review 7.  Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs.

Authors:  Gregory J Digby; P Jeffrey Conn; Craig W Lindsley
Journal:  Curr Opin Drug Discov Devel       Date:  2010-09

8.  Differential effects of allosteric M(1) muscarinic acetylcholine receptor agonists on receptor activation, arrestin 3 recruitment, and receptor downregulation.

Authors:  Albert A Davis; Craig J Heilman; Ashley E Brady; Nicole R Miller; Maya Fuerstenau-Sharp; Bonnie J Hanson; Craig W Lindsley; P Jeffrey Conn; James J Lah; Allan I Levey
Journal:  ACS Chem Neurosci       Date:  2010-08-18       Impact factor: 4.418

9.  Disease-Modifying Effects of M1 Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model.

Authors:  Evan P Lebois; Jason P Schroeder; Thomas J Esparza; Thomas M Bridges; Craig W Lindsley; P Jeffrey Conn; David L Brody; J Scott Daniels; Allan I Levey
Journal:  ACS Chem Neurosci       Date:  2017-03-07       Impact factor: 4.418

10.  Distinct roles of β-arrestin 1 and β-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1).

Authors:  Kwang H Ahn; Mariam M Mahmoud; Joong-Youn Shim; Debra A Kendall
Journal:  J Biol Chem       Date:  2013-02-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.